Overview

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Ranibizumab, an effective antineovascular drug, will be studied for safety and efficacy in pterygium, a neovascular disorder of the ocular surface.
Phase:
Phase 1
Details
Lead Sponsor:
University of New Mexico
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab